ArticleMicrobiota and host2025
Indole dysbiosis and mucosal inflammation.
Article in Microbiota and host, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Integrated multi-omics analysis uncovers cervicovaginal ecological networks and their association withInfection and immunity · 2026Article
- The Gut-Pancreas Axis in Type 1 Diabetes: Emerging Insights into Microbiota and Immune Interactions.International journal of molecular sciences · 2026Review
- Deoxycholic acid promotes anxiety- and depression-like behaviors in mice via modulation of the gut microbial metabolite indole-3-propionic acid.Frontiers in immunology · 2026Article
- Gut microbiota-derived metabolites target C5AR1/KDM2A/HCAR3 axis in inflammatory bowel disease: a multi-machine learning algorithms and molecular docking study.Frontiers in cellular and infection microbiology · 2026Article
- Crohn's disease: research progress in decoding pathogenic multi-network and precision management of artificial intelligence radiomics.Frontiers in immunology · 2026Review
- Baseline gut microbiome features associated with fecal calprotectin response to exclusive enteral nutrition in pediatric Crohn's disease.Frontiers in pediatrics · 2026Article
- Gut microbiota-derived metabolites in immunomodulation and gastrointestinal cancer immunotherapy.Frontiers in immunology · 2025Review
- Physical capacity modulates intestinal barrier dysfunction in functional disorders: phenotype-specific patterns in fibromyalgia and irritable bowel syndrome.Frontiers in physiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The inflammatory bowel diseases (IBD) coincide with shifts in the composition of the microbiota. Since the gastrointestinal (GI) epithelium is anatomically positioned to provide a selective barrier between the microbiota and host lamina propria, this barrier is essential for intestinal homeostasis. Decades-old studies have appreciated that byproducts of the microbiota provide an essential communication network to the host. More recent work has identified microbial-derived metabolites that support multiple functions within the GI mucosa. One such family of metabolites are the indoles, tryptophan-derived molecules that signal within the microbiota and importantly, provide anti-inflammatory properties within the host mucosa. Here, we review the topic of indole production and signaling in the healthy and diseased mucosa.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.